BrainScope holds the distinction of being one of the first FDA-approved AI/ML devices in neurology, with its EEG-based traumatic brain injury assessment demonstrating 99% sensitivity for intracranial hemorrhage detection and documented 50% reductions in unnecessary CT scans at major health systems. Its PMA-level regulatory status is a significant competitive moat in the point-of-care brain injury assessment segment.